查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997470

骨关节炎治疗市场：按治疗方法、给药途径、最终用户和分销管道分類的全球市场预测，2026-2032 年

Osteoarthritis Therapeutics Market by Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，骨关节炎治疗市场价值将达到 55.5 亿美元，到 2026 年将成长至 59.7 亿美元，到 2032 年将达到 93.5 亿美元，复合年增长率为 7.72%。

主要市场统计数据
基准年 2025 55.5亿美元
预计年份：2026年 59.7亿美元
预测年份 2032 93.5亿美元
复合年增长率 (%) 7.72%

对当前骨关节炎治疗范式和不断发展的跨学科护理路径进行简明扼要且权威的概述，这些路径影响着相关人员的决策。

骨关节炎仍然是最常见的退化性关节疾病之一，持续引发临床关注和跨领域创新，旨在缓解疼痛、促进功能恢復并延缓或避免侵入性手术。近年来，治疗方法日趋融合，涵盖了从保守疗法和辅助疗法到先进的外科手术，这反映出以患者为中心、个体化的治疗路径正在转变，力求在控制症状和长期保护关节之间取得平衡。临床医生、保险公司和医疗保健机构越来越重视多学科管理，将药物治疗、物理治疗、生活方式干预和选择性治疗相结合，力求在最大限度减少副作用的同时优化治疗效果。

这是重塑骨关节炎治疗模式的关键转折点，涵盖多方面护理、生物製药、数位化復健以及以价值主导的报销体系的整合。

在骨关节炎治疗领域，正在发生一些变革性的变化，这些变化正在重塑临床实践和商业策略。首先，治疗方式明显转向多方面综合治疗，将针灸、按摩疗法和营养补充剂等辅助疗法与传统药物治疗和针对性手法治疗相结合。这种综合模式认识到患者症状的多样性，并强调制定个人化的治疗方案，从而有可能减少患者对全身性镇痛药的长期依赖。

本研究评估了整体年关税变化和贸易政策调整将如何影响骨关节炎治疗的供应链、采购经济和商业化时间表。

近期关税和贸易方面的动态可能会对骨关节炎药物市场产生重大影响，因为这会影响进口到美国的医疗设备、植入和某些药品原料的投入成本。对医疗设备和用于製造植入、关节镜检查设备以及某些注射药物的原料征收更高的关税，可能会导致供应商的接收成本上升，促使製造商筹资策略、实现供应商多元化，并将製造地转移到其他地区。因此，在洽谈资本投资和植入合约时，医院和诊所可能会面临压力，需要争取更高的价值、延长采购週期，或在条件允许的情况下优先选择国内生产的替代品。

基于全面细分的洞察，将治疗方法、给药途径、医疗保健服务环境和分销管道与临床和商业性进入因素联繫起来。

一套精细的市场区隔框架揭示了每种治疗类型、给药途径、最终用户和分销管道独特的需求驱动因素、治疗路径和商业性需求。根据治疗类型，市场涵盖了针灸、按摩疗法和营养补充剂等辅助疗法，以及从皮质类固醇注射、透明质酸注射到非类固醇消炎剂和鸦片类药物等药物疗法。物理治疗仍然是保守治疗的核心，而外科治疗则包括关节镜、全关节重建和截骨术。特别是股骨和胫骨截骨术，需要不同的外科技术和植入选择。每种治疗路径都有不同的证据阈值、患者接受度趋势和报销机制，这些因素都会影响其应用曲线和医疗服务提供者的奖励。

将患者人口统计、报销框架和临床基础设施与全球市场差异化的进入管道联繫起来的区域战略考量。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的医疗服务取得、应用和战略重点，每个地区都拥有独特的临床基础设施、报销框架和患者群体特征。在美洲，整合式医疗保健系统和私营部门的创新推动了微创手术和先进注射药物的快速普及，同时，与保险公司的谈判和基于价值的合约也日益影响着保险覆盖范围的决策和处方药清单。同时，欧洲、中东和非洲地区的监管环境和采购模式则呈现多样化的特征。该地区既包括技术水平高、支付方成熟的市场，也包括那些因成本限制和医疗服务获取差异而倾向于保守治疗和可扩展康復方案的地区。

这种以创新为重点的竞争情报揭示了临床证据、伙伴关係和服务模式如何重新定义骨关节炎治疗的领导地位。

骨关节炎治疗市场的竞争动态呈现出老牌企业与灵活敏捷的新兴企业并存的局面，而差异化竞争日益依赖于临床证据的强度、治疗路径的整合能力以及服务交付能力。领先的製药和医疗设备公司持续投资于注射剂、植入材料和手术器材的渐进式创新改进，而新参与企业则专注于颠覆性方法，例如再生医学、新型生物製药和数位化復健平台。製造商、专科诊所和数位化供应商之间的伙伴关係与协作正在加速商业性进程，并促成能够将临床结果与支付方价值目标相契合的综合护理提案。

针对製造商、医疗保健提供者和支付方的具体策略措施，以加快实证实践的采用，确保报销，并加强供应链的韧性。

产业领导者应推动一系列切实可行且影响深远的倡议，以应对当前骨关节炎治疗的现状并实现永续价值。首先，临床开发应与支付方和医疗服务提供者关注的可操作终点保持一致，例如功能改善、疗效持续以及对后续手术率的影响，同时将真实世界数据 (REW) 的收集纳入核准后计划，以支持报销和分销。其次，应制定与分销通路和终端用户需求相符的商业化策略。具体而言，这应包括确保医院药房能够提供特製注射药物，透过线上药局为门诊患者提供服务，以及与诊所和復健中心合作建立多方面的护理路径。

采用严谨的三角测量调查方法，结合临床证据审查、相关人员访谈和通路分析，为策略建议奠定基础。

本分析整合了基于三角测量法的调查方法，结合了结构化文献综述、专家访谈和分销管道分析，确保了分析的深度和实用性。结构化文献综述涵盖了同行评审的临床研究、监管指南和专业学会建议，使治疗主张与最新的临床证据相符。对临床医生、采购经理和销售主管的专家访谈，提供了对推广障碍、处方趋势和支付方谈判动态的背景理解。同时，分销管道分析检验了医院药局、线上药局和零售药局之间分销的细微差异，反映了不同治疗方法对物流和病患取得药物的影响。

该摘要阐明了将临床证据、已建立的分销系统和营运弹性与骨关节炎治疗的长期成功联繫起来所面临的战略挑战。

总之，骨关节炎的治疗正处于临床需求、技术创新和不断发展的医疗服务模式的交会点。能够将适应给药途径、医疗服务环境和分销实际情况的实用商业策略与可靠的临床证据相结合的相关人员，将最有能力为患者和支付方提供差异化的价值。辅助治疗方法、标靶药物治疗、物理治疗和外科手术技术的相互作用凸显了建立能够适应患者多样性和当地医疗系统限制的综合护理路径的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的骨关节炎治疗市场

  • 辅助疗法
    • 针刺
    • 按摩疗法
    • 营养补充品
  • 药物治疗
    • 皮质类固醇注射
    • 玻尿酸注射
    • 非类固醇消炎剂（NSAIDs）
    • 阿片类药物
  • 物理治疗
  • 外科手术
    • 关节镜
    • 人工关节重建手术
    • 截骨术
      • 股骨截骨术
      • 胫骨截骨术

第九章：骨关节炎治疗市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用
  • 经皮吸收

第十章：骨关节炎治疗市场：依最终用户划分

  • 诊所
  • 医院
  • 復健中心

第十一章 骨关节炎治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 骨关节炎治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 骨关节炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 骨关节炎治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国骨关节炎治疗药物市场

第十六章：中国骨关节炎治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Ferring BV
  • Fidia Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-DD6333AE50BA

The Osteoarthritis Therapeutics Market was valued at USD 5.55 billion in 2025 and is projected to grow to USD 5.97 billion in 2026, with a CAGR of 7.72%, reaching USD 9.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.55 billion
Estimated Year [2026] USD 5.97 billion
Forecast Year [2032] USD 9.35 billion
CAGR (%) 7.72%

A concise and authoritative overview of current osteoarthritis therapeutic paradigms and evolving multidisciplinary care pathways shaping stakeholder decision-making

Osteoarthritis remains one of the most prevalent degenerative joint disorders, driving sustained clinical attention and cross-sector innovation aimed at alleviating pain, restoring function, and delaying or avoiding invasive procedures. Recent years have seen a convergence of therapeutic approaches that span conservative complementary modalities through to advanced surgical interventions, reflecting a patient-centric shift toward personalized care pathways that balance symptom control with long-term joint preservation. Clinicians, payers, and providers increasingly emphasize multidisciplinary management, combining pharmacologic options with physical therapy, lifestyle interventions, and selective procedural therapies to optimize outcomes while minimizing adverse effects.

Concurrently, technology-enabled care models and digital therapeutics have expanded the toolkit available to clinicians and patients, enabling remote monitoring, adherence support, and rehabilitation at scale. These developments create new opportunities and complexities for stakeholders across the ecosystem, as they must reconcile clinical efficacy, reimbursement dynamics, and patient preferences. Importantly, regulatory scrutiny and safety considerations continue to shape the adoption of certain drug classes and intra-articular therapies, necessitating robust evidence generation and post-market surveillance.

As healthcare systems prioritize value-based care and longitudinal outcomes, strategic planning for osteoarthritis therapeutics requires nuanced understanding of treatment pathways, administration routes, and the providers who deliver care. This executive summary synthesizes current trends, structural shifts, and actionable insights that can inform R&D prioritization, portfolio management, and commercial strategies across pharmaceutical, medtech, and service delivery organizations.

Critical inflection points reshaping osteoarthritis treatment models including integration of multimodal care, biologics, digital rehabilitation, and value-driven reimbursement

The landscape of osteoarthritis therapeutics is undergoing several transformative shifts that are recalibrating clinical practice and commercial strategy. First, there is a clear reorientation toward multimodal care that integrates complementary therapies-such as acupuncture, massage therapy, and nutritional supplements-with traditional pharmacologic treatments and targeted procedural approaches. This integrated model acknowledges the heterogeneity of patient presentations and emphasizes individualized care plans that may reduce reliance on long-term systemic analgesics.

Second, advances in biologic and device-based interventions have elevated the role of localized therapies, including refined intra-articular injections and minimally invasive surgical techniques. These modalities aim to achieve symptom relief with lower systemic exposure, and their uptake is influenced by emerging clinical evidence, payer policies, and procedural capacity in outpatient and ambulatory settings. Third, digital health and tele-rehabilitation platforms are scaling access to supervised physical therapy and self-management programs, altering patient engagement and adherence dynamics and enabling providers to extend care beyond traditional brick-and-mortar encounters.

Fourth, payer and procurement strategies are increasingly focused on outcomes and cost-effectiveness, incentivizing care models that demonstrably reduce downstream resource utilization such as hospital readmissions or early joint replacement. Finally, cross-industry collaboration-spanning pharmaceuticals, medical device manufacturers, digital health vendors, and specialty clinics-is driving novel commercial partnerships and bundled care offerings. Together, these shifts demand adaptive strategies that align clinical evidence generation with novel delivery models and evolving reimbursement frameworks.

Assessing how tariff shifts and trade policy adjustments in 2025 can alter supply chains, procurement economics, and commercialization timelines across osteoarthritis therapeutics

Recent policy developments relating to tariffs and trade can exert meaningful influence on the osteoarthritis therapeutics landscape by affecting input costs for devices, implants, and certain pharmaceutical components imported into the United States. Increased duties on medical devices or raw materials used in manufacturing implants, arthroscopy equipment, and certain injectables can lead to higher landed costs for suppliers and may prompt manufacturers to reassess procurement strategies, supplier diversification, and regional manufacturing footprints. In turn, hospitals and clinics negotiating capital purchases and implant contracts may face pressure to extract greater value, extend procurement cycles, or prioritize domestically manufactured alternatives where available.

Moreover, tariffs can create short-term supply chain volatility that impacts inventory planning for hospital pharmacies, retail outlets, and online pharmacies that distribute osteoarthritis therapies. When suppliers anticipate cost headwinds, they often adjust pricing strategies, negotiate differently with distributors, or absorb margins selectively across portfolios, which can influence product availability and promotional investments. For innovators and smaller manufacturers, tariff-driven cost increases can heighten barriers to entry or slow commercialization timelines, particularly for capital-intensive device launches or complex biologic formulations that depend on specialized components.

In response, many stakeholders have accelerated supply chain resilience programs, including nearshoring, dual sourcing, and longer-term supplier agreements to mitigate exposure to tariff volatility. For health systems and group purchasing organizations, a strategic response includes scenario planning that integrates procurement flexibility, contract clauses addressing input-cost variability, and clinical substitution pathways that preserve care quality while managing cost. Ultimately, the cumulative impact of tariff changes in 2025 emphasizes the imperative for integrated commercial and supply chain strategies that protect access while sustaining innovation across therapeutics and devices.

Comprehensive segmentation-driven insights that map treatment modalities, administration routes, provider settings, and distribution channels to clinical and commercial adoption drivers

A nuanced segmentation framework illuminates distinct demand drivers, care pathways, and commercial imperatives across treatment type, route of administration, end-user, and distribution channel. Based on treatment type, the market comprises complementary therapies that include acupuncture, massage therapy, and nutritional supplements alongside drug therapy spanning corticosteroid injections, hyaluronic acid injections, non-steroidal anti-inflammatory drugs, and opioids; physical therapy modalities remain central to conservative management; and surgical solutions encompass arthroscopy, joint replacement, and osteotomy with femoral and tibial osteotomy subtypes that require distinct surgical expertise and implant considerations. Each of these treatment pathways has different evidence thresholds, patient acceptance dynamics, and reimbursement profiles, which in turn influence adoption curves and provider incentives.

Based on route of administration, therapies arrive via injectable, oral, topical, and transdermal pathways, with injectables attracting attention for their targeted delivery and potential for reduced systemic exposure, while oral and topical agents remain important for broad symptom management and ease of use. Based on end-user, clinics, hospitals, and rehabilitation centers each serve differentiated roles: clinics and outpatient centers emphasize access and conservative care delivery, hospitals provide surgical and acute interventions, and rehabilitation centers focus on intensive post-procedural recovery and functional restoration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies mediate how therapies reach patients, with each channel presenting unique considerations around inventory management, cold-chain logistics for certain injectables, patient counseling, and reimbursement coding.

Taken together, this segmentation underscores that product development, clinical trial design, and commercial planning must align with the practical realities of administration route, provider capabilities, and distribution pathways. Transitioning from clinical proof-of-concept to widespread adoption often requires tailored evidence packages, clinician education, and distribution agreements calibrated to the dominant channels serving target patient cohorts.

Regional strategic considerations tying patient demographics, reimbursement frameworks, and clinical infrastructure to differentiated adoption pathways across global markets

Regional dynamics shape access, adoption, and strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct clinical infrastructures, reimbursement frameworks, and patient demographics. In the Americas, integrated health systems and private sector innovation support rapid uptake of minimally invasive procedures and advanced injectables, while payer negotiation and value-based contracting increasingly determine coverage decisions and formulary placement. Conversely, Europe, Middle East & Africa exhibit heterogeneous regulatory landscapes and procurement models; this region combines markets with high procedural capacity and sophisticated payers alongside settings where cost containment and access gaps emphasize conservative care and scalable rehabilitation solutions.

Asia-Pacific presents a diverse mix of highly innovative markets with strong manufacturing capabilities and rapidly growing clinical volumes alongside emerging healthcare systems investing in surgical capacity and rehabilitation services. Across all regions, demographic shifts toward aging populations and rising prevalence of osteoarthritis amplify demand for effective, durable interventions and scalable care pathways. Regional reimbursement nuances influence the prioritization of certain therapies, with some payers favoring interventions demonstrating demonstrable reductions in downstream surgical interventions and others prioritizing short-term cost containment.

Given these regional contours, manufacturers and service providers must tailor market entry strategies, evidence generation plans, and commercial models to local regulatory expectations, distribution norms, and provider reimbursement incentives. Strategic partnerships with regional distributors, capacity-building programs for surgeons and rehabilitation teams, and differentiated pricing strategies are critical levers to bridge clinical innovation with sustainable access across diverse geographies.

Competitive and innovation-focused intelligence revealing how clinical evidence, partnerships, and service models are redefining leadership in osteoarthritis therapeutics

Competitive dynamics within osteoarthritis therapeutics reflect a blend of established incumbents and agile challengers, with differentiation increasingly driven by the strength of clinical evidence, pathway integration capabilities, and service-enablement. Leading pharmaceutical and device organizations continue to invest in incremental innovation-refinements to injectables, implant materials, and surgical instrumentation-while newer entrants emphasize disruptive approaches such as regenerative therapies, novel biologics, and digitally enabled rehabilitation platforms. Partnerships and alliances between manufacturers, specialty clinics, and digital vendors are accelerating commercial reach and enabling bundled care propositions that align clinical outcomes with payer value goals.

R&D pipelines emphasize improved safety profiles, targeted delivery, and longer durability of effect, with clinical programs designed to generate real-world evidence that supports favorable reimbursement decisions. For surgical device makers and implant suppliers, manufacturing scale, cost-efficient supply chains, and service models that support surgeon training and OR efficiency have become competitive differentiators. At the same time, distributors and pharmacy channels are optimizing logistics and patient services to support therapy adherence and home-based care models.

Strategic M&A activity and licensing deals have favored entities that can complement broader portfolios with specialty devices, high-value biologics, or digital infrastructure that enhances long-term patient monitoring. For commercial leaders, the priority is to align product positioning with provider workflows and payer benchmarks, invest in clinician education to accelerate uptake, and deploy health economics evidence that articulates the value proposition in terms of patient outcomes and resource utilization.

Actionable strategic measures for manufacturers, providers, and payers to accelerate evidence-informed adoption, secure reimbursement, and strengthen supply chain resilience

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate the current osteoarthritis therapeutics landscape and capture sustainable value. First, align clinical development with pragmatic endpoints that matter to payers and providers, including measures of functional improvement, durability of effect, and impact on downstream surgical rates, while integrating real-world evidence generation into post-approval plans to support reimbursement and uptake. Second, design commercialization strategies that match distribution channels and end-user needs: ensure hospital pharmacy readiness for specialty injectables, support online pharmacy patient services for outpatient therapies, and partner with clinics and rehabilitation centers to embed multimodal care pathways.

Third, invest in supply chain resilience and cost containment measures to mitigate exposure to tariff-related cost volatility and component shortages, including dual sourcing, regional manufacturing, and long-term supplier agreements. Fourth, develop bundled service offerings and clinician training programs that reduce barriers to adoption for novel surgical techniques and device platforms, and leverage digital rehabilitation and remote monitoring to extend patient engagement beyond the clinic. Fifth, cultivate payer engagement early to negotiate coverage pathways and value-based contracting that reflect long-term outcomes. Finally, prioritize cross-functional collaboration across R&D, commercial, regulatory, and supply chain teams to ensure coordinated launch execution and to adapt rapidly to evolving clinical evidence and reimbursement landscapes.

A rigorous, triangulated research methodology combining clinical evidence review, stakeholder interviews, and distribution channel analysis to underpin strategic recommendations

This analysis synthesizes insights derived from a triangulated research methodology combining structured literature review, expert interviews, and channel analysis to ensure both depth and practical relevance. The structured literature component encompassed peer-reviewed clinical studies, regulatory guidance, and specialty society recommendations to ground therapeutic claims in contemporary clinical evidence. Expert interviews with clinicians, procurement leaders, and commercial executives provided contextual understanding of adoption barriers, procedural trends, and payer negotiation dynamics, while channel analysis examined distribution nuances across hospital pharmacies, online pharmacies, and retail pharmacies to reflect the logistics and patient access implications of different therapies.

Where applicable, public regulatory filings and clinical trial registries informed assessment of pipeline priorities and safety considerations. The methodology emphasized cross-validation across data sources to enhance reliability and minimize bias, and findings were reviewed by practicing clinicians and industry experts to ensure practical applicability. Limitations of the research approach include heterogeneity in reporting standards across geographies and the evolving nature of tariff and trade policy, which necessitates ongoing monitoring. Nevertheless, the methodology provides a robust foundation for strategic decision-making by combining empirical clinical evidence, stakeholder perspectives, and operational channel insights.

Concluding synthesis that crystallizes strategic imperatives linking clinical evidence, distribution readiness, and operational resilience to long-term success in osteoarthritis care

In conclusion, osteoarthritis therapeutics occupy a dynamic intersection of clinical need, technological innovation, and evolving care delivery models. Stakeholders that successfully bridge robust clinical evidence with pragmatic commercial strategies-attuned to route of administration, provider settings, and distribution realities-will be best positioned to deliver differentiated value to patients and payers. The interplay of complementary therapies, targeted drug interventions, physical therapy, and surgical techniques underscores the necessity of integrated care pathways that are adaptable to patient heterogeneity and regional system constraints.

Supply chain resilience and strategic responses to tariff pressures will remain important operational considerations, particularly for devices and components with complex sourcing profiles. Competitive leadership will favor organizations that combine credible outcomes data, clinician engagement programs, and distribution capabilities across hospital, online, and retail channels. Ultimately, the most effective approaches are those that align product and service design with measurable improvements in patient function and quality of life while providing clear economic value to payers and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Therapeutics Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Acupuncture
    • 8.1.2. Massage Therapy
    • 8.1.3. Nutritional Supplements
  • 8.2. Drug Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.4. Opioids
  • 8.3. Physical Therapy
  • 8.4. Surgery
    • 8.4.1. Arthroscopy
    • 8.4.2. Joint Replacement
    • 8.4.3. Osteotomy
      • 8.4.3.1. Femoral Osteotomy
      • 8.4.3.2. Tibial Osteotomy

9. Osteoarthritis Therapeutics Market, by Route of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Osteoarthritis Therapeutics Market, by End-User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Rehabilitation Centers

11. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoarthritis Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Osteoarthritis Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Osteoarthritis Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Osteoarthritis Therapeutics Market

16. China Osteoarthritis Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Cipla Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. Endo International plc
  • 17.13. Ferring B.V.
  • 17.14. Fidia Farmaceutici S.p.A
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Johnson & Johnson Services Inc.
  • 17.17. Merck & Co.
  • 17.18. Pfizer Inc.
  • 17.19. Sanofi S.A.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)